Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
about
Aberrant Wnt Signaling in LeukemiaThe role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemiaTargeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibSecondary mutations as mediators of resistance to targeted therapy in leukemiaThe cell survival pathways of the primordial RNA-DNA complex remain conserved in the extant genomes and may function as proto-oncogenesEvolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cellsPreventing clonal evolutionary processes in cancer: Insights from mathematical models.Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinibIbrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.Rethinking clinical response and outcome assessment in a biologic age.Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia.Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells.Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection.The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes.Mathematical modeling of the impact of cytokine response of acute myeloid leukemia cells on patient prognosis.Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia.
P2860
Q26738411-8FD37811-18CD-4AA2-B7EA-EEE4FF1E336FQ26775506-30DCDEC6-4CE2-436C-A8E3-2B632D061632Q27025812-AF2A5AA9-5D4A-4015-BB86-5EBBF867C6B2Q28087213-21C2554E-BA13-4DB3-ADED-C7A5F96E2688Q28649653-DB629D15-E4C9-4561-B714-2A7D2009D3D8Q34280885-53AC4533-77D2-410D-B81E-F9AD211EB4E6Q35110849-004E805F-E6E8-47D6-9F54-11DEA39DCD01Q35895622-79949DB5-84C7-40D8-AA01-FB93EDC8CDFEQ36172601-55ADDC24-7AF4-4A43-AE19-A872B9448394Q36782516-50900FCA-CE54-4823-8E97-BACFF4E30251Q37528067-133A5013-6E3C-4A1F-9A83-5C883B506956Q37599562-C3425B10-09CB-4097-AB7E-D91847E37F27Q38480777-7CEDE3E0-350D-4824-A26C-0814640280E0Q38544216-EFD87979-4A1C-4411-BF2B-D580699484C7Q38550810-930C54D2-4A76-454C-BC4D-25D40CDB58CAQ38760676-AA819B90-E94F-446B-89BD-05B5EC9BC5E8Q39006397-7ABC94E6-9D9A-42DA-B79A-5857A2356A27Q39065374-30270E5C-51AC-4467-97E7-2681319113B7Q40537266-A73E8F52-3259-44B2-8568-311F4E2163A6Q41708887-FA44074D-D5D2-4F00-AD83-C9CE803E3475Q41848521-9736B4BB-3D1E-4950-864D-867D24D730F0Q42625287-6885DB26-1395-49D2-8A4D-98094C03E645Q46566477-424E7014-BC1F-43ED-BE23-82A38D45BA4CQ47424531-3F24560F-9ECF-4145-BDAF-4006C64E3BF9Q48257200-D6FA1D7A-6C4A-4CFD-A039-487E4AAEA108Q49402805-E1F4C6D4-98A8-47FD-AFEB-46D3BEADCDE1Q53963822-A6A6C8EF-6AEF-4D0B-86B6-7450B5F3FA1EQ55061968-03316960-8C7A-4B5B-B872-0C3EB5B3D48D
P2860
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Kinetics of CLL cells in tissu ...... h the BTK inhibitor ibrutinib.
@ast
Kinetics of CLL cells in tissu ...... h the BTK inhibitor ibrutinib.
@en
Kinetics of CLL cells in tissu ...... h the BTK inhibitor ibrutinib.
@nl
type
label
Kinetics of CLL cells in tissu ...... h the BTK inhibitor ibrutinib.
@ast
Kinetics of CLL cells in tissu ...... h the BTK inhibitor ibrutinib.
@en
Kinetics of CLL cells in tissu ...... h the BTK inhibitor ibrutinib.
@nl
prefLabel
Kinetics of CLL cells in tissu ...... h the BTK inhibitor ibrutinib.
@ast
Kinetics of CLL cells in tissu ...... h the BTK inhibitor ibrutinib.
@en
Kinetics of CLL cells in tissu ...... h the BTK inhibitor ibrutinib.
@nl
P2093
P2860
P50
P1433
P1476
Kinetics of CLL cells in tissu ...... h the BTK inhibitor ibrutinib.
@en
P2093
Danelle James
Dominik Wodarz
Jan A Burger
Natalia L Komarova
Ohad Benjamini
P2860
P304
P356
10.1182/BLOOD-2014-02-554220
P407
P577
2014-05-14T00:00:00Z